Machine signal
Active cluster sell — 5 distinct insiders, $1.1M, window ends Aug 17, 2026.
Figures computed from official regulatory filings — .
Analysttarget 19.5 USD (+49%) · consensus 4.25/5 · 7 buy · 0 hold · 1 sell
Ownershipinsiders 1.65% · institutions 104.69% · short 33.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Replimune Group, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
7 buys262 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Astley-Sparke Philip | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hill Emily Luisa | Sell | $132.2K | SEC |
| Xynos Konstantinos | Sell | $148.5K | Unusual size | SEC |
| Schwendenman Andrew | Sell | $99K | Unusual size | SEC |
| Patel Sushil | Sell | $510.3K | Unusual size | SEC |
| Hill Emily Luisa | Sell | $148.5K | SEC |
| BAKER BROS. ADVISORS LPtrack record | BuyD (derivative) | $1.5M | SEC |
| BAKER BROS. ADVISORS LPtrack record | BuyD (derivative) | $31.5M | SEC |
| Sarchi Christopher | Sell | $110.9K | Unusual size | SEC |
| Patel Sushil | Sell | $189.6K | SEC |
| Astley-Sparke Philip | Sell | $89.7K | SEC |
| Sarchi Christopher | Sell | $43.8K | SEC |
| Xynos Konstantinos | Sell | $71.2K | SEC |
| Schwendenman Andrew | Sell | $40.1K | SEC |
| Hill Emily Luisa | Sell | $39.7K | SEC |
| BAKER BROS. ADVISORS LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Astley-Sparke Philip | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Balachandran Madhavan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hill Emily Luisa | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BAKER BROS. ADVISORS LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Peeples-Dyer Veleka | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sarchi Christopher | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SLATTERY JOSEPH Ptrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Weinand Dieter | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pucci Paolo | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |